New approaches for the immunotherapy of acute myeloid leukemia.
Ontology highlight
ABSTRACT: Acute myeloid leukemia (AML) is a set of related diseases characterized by the immortalization and uncontrolled expansion of myeloid precursor cells. Core therapy for AML has remained unchanged for nearly 30 years, and survival rates remain unsatisfactory. However, advances in the immunotherapy of AML have created opportunities for improved outcomes. Enforcing a tumor-specific immune response through the re-direction of the adaptive immune system, which links remarkable specificity with potent cytotoxic effector functions, has proven particularly compelling. This may be coupled with immune checkpoint blockade and conventional therapies for optimal effect. Engineered antibodies are currently in use in AML and the repertoire of available therapeutics will expand. NK cells have shown effectiv
SUBMITTER: Geiger TL
PROVIDER: S-EPMC4628787 | biostudies-literature | 2015 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA